August 22, 2002

Thrombotic Microangiopathies

Key Points

Key points are not available for this paper at this time.

Abstract

This article reviews the substantial progress made in understanding the thrombotic microangiopathies. The mechanisms of both thrombotic thrombocytopenic purpura and the hemolytic–uremic syndrome are considered.

Bookmark

Cite This Study

Joel L. Moake (Thu,) studied this question.

synapsesocial.com/papers/6a1be5306f692abb725ef4bc https://doi.org/https://doi.org/10.1056/nejmra020528

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The United States National Prospective Hemolytic Uremic Syndrome Study: Microbiologic, Serologic, Clinical, and Epidemiologic Findings2001 · 314 citations
2Haemolytic uraemic syndrome: therapeutic effect of plasma infusion.1982 · 78 citations
3Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease2001 · 259 citations
4Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura2001 · 836 citations
5Purification of human von Willebrand factor–cleaving protease and its identification as a new member of the metalloproteinase family2001 · 610 citations

Bookmark